Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
NCT02968641 · Eiger BioPharmaceuticals · PHASE2 · withdrawn · last registry update 2021-02-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was initially planned to enroll patients in Mongolia. However, due to challenges in setting it up in Mongolia, this study was later determined not to be initiated.” | – | Registry record, Eiger BioPharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FNTA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-08Phase 3 first posted: Soroka University Medical Center, Lonafarnib + Ritonavir (NCT05229991)
- 2021-12-01Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Peg-interferon lambda + Lonafarnib (NCT03600714)
- 2020-07-31Also stopped (withdrawn): Jonsson Comprehensive Cancer Center, gemcitabine hydrochloride + lonafarnib (NCT00020774)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision